ABSK021

Phase 2Small molecule

AAbbisko Therapeutics Co, Ltd

ABSK021 is one of 66 small molecule programs targeting Advanced Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorRecruiting

Chronic Graft Versus Host DiseaseEnrolling by invitation

Advanced Solid TumorPhase 1

Recruiting

Chronic Graft Versus Host DiseasePhase 2

Enrolling by invitation

Competition

Competitive Landscape

56 competitors in Advanced Solid Tumor

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

4 2

Mekinist

Novartis

Phase 2

2 3

Fludara

Sanofi

Phase 2

1 4

Tafinlar

Novartis

Phase 2

1 5

Paraplatin

AAvyxa

Phase 2

3 6

Proleukin

IIovance Biotherapeutics, Inc.

Phase 2

1 7

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 8

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 9

Alimta

SShawn Eagle

Phase 2

1 10

Nubeqa

Bayer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Advanced Solid Tumor

NCT04192344

Clinical

Trials by Indication[1]

Clinical Trial1 trial

A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06322706·36 enrolled

Advanced Solid Tumor1 trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Recruiting·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT04192344·276 enrolled

Chronic Graft Versus Host Disease1 trial

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation·AAbbisko Therapeutics Co, Ltd·Phase 2·NCT06186804·64 enrolled

Unspecified1 trial

ABSK021 Food Effect Study in Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT05280483·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ABSK021. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABSK021 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABSK021. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abbisko Therapeutics Co, Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAbbisko Therapeutics Co, Ltd

ABSK021

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Clinical Trial1 trial

Advanced Solid Tumor1 trial

Chronic Graft Versus Host Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News